Bethany Sensenig

CIK 1899935 · Chief Financial Officer · last filed 2026-06-11

Bethany Sensenig is a Chief Financial Officer who has filed 17 SEC Form 4 insider transactions across 4 companies since 2022. The most recent filing, for KALV, was dated Jun 11, 2026. Across all open-market trades the lifetime net is −$466.1K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $48.8K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$48.8K

Companies

4

Total Filings

17

Lifetime Open-Market Net

-$466.1K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
KalVista Pharmaceuticals, Inc. (KALV) Delisted Director $27.00 $0 2 2026-06-11
ACOG Director 5,489 $8.88 $48.8K $0 1 2026-04-17
SUPN Director 0 $46.88 $0 -$455.1K 7 2026-02-23
9 METERS BIOPHARMA, INC. (NMTR) Delisted Chief Financial Officer 41,077 $0.07 $3.0K -$11.0K 3 2023-04-21

Recent Filings

17 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-11 KalVista Pharmaceuticals, Inc. (KALV) Delisted Disp (D) $0 EDGAR
2026-04-17 ACOG Grant (A) +5,489 $0 EDGAR
2026-02-23 SUPN Mixed -$228.3K EDGAR
2026-02-20 SUPN Grant (A) $0 EDGAR
2026-02-19 SUPN Notice (144) −4,475 -$224.6K EDGAR
2025-10-02 KalVista Pharmaceuticals, Inc. (KALV) Delisted Grant (A) $0 EDGAR
2025-08-18 SUPN Sell (S) −5,369 -$226.8K EDGAR
2025-08-14 SUPN Notice (144) −5,369 -$228.9K EDGAR
2025-02-24 SUPN Mixed +5,369 $0 EDGAR
2025-02-21 SUPN Grant (A) $0 EDGAR
Showing 110 of 17
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.